drug-resistance
(3)
Pinetree Therapeutics
Pinetree Therapeutics is a Cambridge, Massachusetts biotech founded in 2019 that develops antibody-based targeted protein degraders for cancer. Its AbReptor and TAER-TAB platforms use modular bispecific and multispecific antibodies to hijack the body's own lysosomal machinery and eliminate disease-driving membrane-bound and extracellular proteins - including drug-resistant receptor tyrosine kinases that conventional inhibitors cannot reach. Led by founder and CEO Ho-Juhn Song, Ph.D., the preclinical company has raised roughly $111M to date, struck a $500M+ EGFR-degrader option deal with AstraZeneca, and is advancing lead oncology programs toward Phase I.
Sanavia Oncology Inc.
Sanavia Oncology is a New York-based biotech company developing next-generation cancer immunotherapies for patients who don't benefit from existing treatments. Its proprietary platform pairs high-throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and artificial intelligence to discover novel, clinically relevant cancer-specific epitopes in drug-resistant tumors, then generates antibodies with atomic-level specificity to those targets. The company is building antibody drug conjugates (ADCs), bispecific T cell engagers (TCEs) and CAR-T therapies - led by its SANA-01 ADC - and is backed by Two Bear Capital.
Ho-Juhn Song
Ho-Juhn Song is the co-founder and CEO of PineTree Therapeutics, a Cambridge, Massachusetts biotech building next-generation targeted protein degraders to overcome drug resistance in cancer. A geneticist by training with a Ph.D. from Oregon State University and a former project team leader at the Novartis Institutes for BioMedical Research, Song founded PineTree in 2019 around the AbReptor platform, which degrades membrane-bound and extracellular proteins that conventional drugs struggle to reach. Under his leadership the company licensed its lead EGFR degrader to AstraZeneca in a deal worth more than $500 million in potential milestones and closed an oversubscribed $47 million Series B in October 2025.